Zelluna Expands Solid Tumor Pipeline with AI-Engineered TCR Collaboration
Event summary
- Zelluna partners with Etcembly to engineer KKLC1-targeting TCRs for its TCR-NK platform using AI.
- Collaboration builds on prior successful engineering of MAGE-A4 TCR for ZI-MA4-1, approved for clinical testing in February 2026.
- KKLC1 is a validated cancer antigen expressed in multiple difficult-to-treat solid tumors.
- In-vitro data demonstrating safety, specificity, and functional activity expected in Q4 2026.
- Engineered receptors will be fully owned by Zelluna and developed for its proprietary TCR-NK platform.
The big picture
This collaboration underscores the growing trend of AI-driven drug discovery in biotech, particularly in the engineering of immune receptors for cancer therapy. By leveraging Etcembly's EMLy™ platform, Zelluna aims to accelerate the development of highly precise and potent treatments for solid tumors, a segment with significant unmet medical needs. The success of this partnership could set a precedent for future AI-guided TCR engineering collaborations in the industry.
What we're watching
- Technical Validation
- Whether the AI-guided in silico engineering will deliver TCRs with enhanced specificity and potency as promised.
- Pipeline Expansion
- The pace at which Zelluna can expand its product portfolio beyond MAGE-A4 to address a broader spectrum of solid cancers.
- Clinical Progress
- How the in-vitro data expected in Q4 2026 will translate into the clinical development timeline for KKLC1-targeting TCRs.
Related topics